vendredi 19 octobre 2018

Onco Actu du 19 octobre 2018

1. Biologie

Science Surgery: ‘How quickly do tumours develop?’ [Cancer Research UK]

Researchers Explore a Cancer Paradox [NY Times]

4.2 Dép., diag. & prono. - Génome

Combining data from the genetic testing techniques can guide patient care, scientists say. [The Scientist]

White-people-only DNA tests show how unequal science has become [MIT Technology Review]

4.3 Dép., diag. & prono. - Industriels

Amgen sharpens focus on genetic sequencing with $66M investment [EndPoints]

Oxford Nanopore secures £50m from Amgen to develop pocket-sized DNA sequencer [The Telegraph]

5.12 Immunothérapies

Fighting Cancer with Natural Killer Cells [NIH Director's Blog]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

The Parker Institute for Cancer Immunotherapy Partners with Xyphos Biosciences to Develop Universal Programmable CAR-T Cells for Cancer Treatment [Parker Institute]

Parker Institute backs an upstart biotech looking to develop a new, convertible CAR-T [EndPoints]

5.12.3 Immunothérapies-combinaisons

Merck's Keytruda, ready to challenge Bristol-Myers Squibb, posts kidney cancer combination win [FiercePharma]

A Year Early, Merck Touts Good Kidney Cancer News to Push Rival BMS [Xconomy]

Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pfizer’s Inlyta® (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advanced or Metastatic Renal Cell Carcinoma [Merck]

5.12.5 Immunothérapies - Pharma

FDA slaps a full hold on Affimed’s T cell engager in wake of a lethal reaction [EndPoints]

5.2 Pharma

Can Pfizer's new breast cancer drug Talzenna really make a dent in the PARP field? [FiercePharma]

5.2.2 Pharma - Fusions & Acquisitions

Novartis buys Endocyte for $2.1 billion, causing an outspoken critic to admit he was badly wrong [STAT]

Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms [Novartis]

5.6.16 ESMO - Appareil digestif

Women more prone to selected oesophagogastric cancer chemotherapy side-effects [ESMO 2018 Press Release]

5.6.17 ESMO - Foie

Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden [Novartis]

5.6.6 ESMO - Sein

One in six premenopausal early breast cancer patients do not adhere to hormonal therapy [ESMO 2018 Press Release]

6. Lutte contre les cancers

Project Baseline Aims to Ward Off Illness Before We Get Sick [NY Times]

6.1 Observation

New Statistical Method Estimates Time to Metastasis of Breast Cancer in U.S. Women [AACR]

6.11 Patients

Flat Out: Rejecting Breast Reconstruction [NY Times]

Researchers, cancer patients, and philanthropists launch "Count Me In" [Broad Institute]

Researchers Want Cancer Patients To Share Their Medical Information In Search of Cures [Time]

6.7 DMP, Big Data & applis

The future of healthcare: our vision for digital, data and technology in health and care [GOV.UK]